← 返回

B 细胞增强 IL-1β驱动的三阴性乳腺癌侵袭性

英文原题:B cells enhance IL-1 beta driven invasiveness in triple negative breast cancer.

查看英文原题

B cells enhance IL-1 beta driven invasiveness in triple negative breast cancer.

PubMed 2025/01/16(内容时间) Sci Rep Q1 · IF 4.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

三阴性乳腺癌(TNBC)是一种侵袭性亚型,常以高淋巴细胞浸润为特征,包括肿瘤浸润B细胞(TIBs)。这些细胞甚至存在于TNBC的早期阶段,并与微浸润相关。

本研究表明,将TNBC细胞与B细胞共培养可增加白细胞介素-1β(IL-1β)的表达和分泌。我们进一步表明,B细胞诱导的IL-1β激活NFκB信号通路,导致靶基因表达升高,并促进IL-1β依赖性的基质金属蛋白酶(MMP)活性、侵袭和迁移增加。对三阴性导管原位癌(DCIS,n = 90)和浸润性TNBC(n = 171)中IL-1β和TIBs的免疫组化分析显示,在DCIS中,TIBs与IL-1β表达和微浸润相关,IL-1β也与复发相关。在浸润性TNBC中,IL-1β表达与TIB密度和分期相关,高IL-1β水平与较差的生存结局相关。这些发现表明,TNBC中早期B细胞的存在可诱导IL-1β分泌,通过IL-1β-NFκB信号通路增强侵袭和迁移能力。这凸显了IL-1抑制剂作为激素受体阴性DCIS和TNBC预防及治疗选择的潜力。

展开英文摘要原文

Triple-negative breast cancer (TNBC) is an aggressive subtype often characterized by high lymphocyte infiltration, including tumor-infiltrating B cells (TIBs). These cells are present even in early stages of TNBC and associated with microinvasion.

This study shows that co-culturing TNBC cells with B cells increases Interleukin-1β (IL-1β) expression and secretion.

We further show that B cell-induced IL-1β activates NFκB signaling, leading to higher expression of target genes and promoting IL-1β-dependent increases in matrix metalloproteinase (MMP) activity, invasion, and migration.

Immunohistochemical analysis of IL-1β and TIBs in triple-negative ductal carcinoma in situ (DCIS, n = 90) and invasive TNBC (n = 171) revealed that in DCIS, TIBs correlated with IL-1β expression and microinvasion, with IL-1β also linked to recurrence. In invasive TNBC, IL-1β expression correlated with TIB density and stage, with high IL-1β levels associated with poorer survival outcomes.

These findings suggest that early B cell presence in TNBC can induce IL-1β secretion, enhancing invasion and mobility through IL-1β-NFκB signaling. This highlights the potential of IL-1 inhibitors as preventive and therapeutic options for hormone receptor-negative DCIS and TNBC.

论文信息

作者
Toney NJ、Opdenaker LM、Frerichs L、Modarai SR、Ma A、Archinal H、Ajayi GO、Sims-Mourtada J
第一作者单位
Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA.United States
通讯作者单位
Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA. jsimsmourtada@christianacare.org.United States
期刊
Scientific reports2025 Jan 16
原文标识
PubMed 39820772 · DOI 10.1038/s41598-025-86064-1